Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1726 to 1740 of 8314 results

  1. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development Reference number: GID-TA11036 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Apraglutide for treating short bowel syndrome [ID6533]

    In development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]

    Awaiting development Reference number: GID-TA11641 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Camlipixant for treating refractory or unexplained chronic cough [TSID12072]

    Awaiting development Reference number: GID-TA11707 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Lomitapide for treating homozygous familial hypercholesterolaemia in people 5 to 17 years [TSID 12085]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Eptinezumab for preventing cluster headache attacks TSID 12087

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date: TBC

    NICE guideline
    In development

  9. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Diltiazem (Anatop, SLV-324, VEN 307) for Anal fissure [TSID 12100]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment [TSID12171]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Doravirine-islatravir for previously untreated HIV-1 infection [TSID12172]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy [TSID12173]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Orforglipron for treating type 2 diabetes [TSID12130]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation